Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER

Circulation 2022;145:575–85 doi: 10.1161/CIRCULATIONAHA.121.055459

The effects of once-weekly semaglutide and once-daily liraglutide were assessed. Pooled and by-trial data from SUSTAIN 6 and LEADER were assessed for albuminuria change, eGFR change, and time to persistent eGFR reduction from baseline.


LinkedIn